Skip to main content

Advertisement

Log in

Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?

Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

High-density lipoprotein cholesterol (HDL-C) has been shown in epidemiologic studies to be associated with cardiovascular (CV) risk and thus significant efforts have been focused on HDL-C modulation. Multiple pharmaceutical agents have been developed with the goal of increasing HDL-C. Niacin, the most widely used medication to raise HDL-C, increases HDL-C by up to 25 % and was shown in multiple surrogate end point studies to reduce CV risk. However, two large randomized controlled trials of niacin, AIM-HIGH and HPS2-THRIVE, have shown that despite its effects on HDL-C, niacin does not decrease the incidence of CV events and may have significant adverse effects. Studies of other classes of agents such as cholesteryl ester transfer protein (CETP) inhibitors have also shown that even dramatic increases in HDL-C do not necessarily translate to reduction in clinical events. While these findings have cast doubt upon the importance of HDL-C modulation on CV risk, it is becoming increasingly clear that HDL function-related measures may be better targets for CV risk reduction. Increasing ApoA-I, the primary apolipoprotein associated with HDL, correlates with reduced risk of events, and HDL particle concentration (HDL-P) inversely associates with incident CV events adjusted for HDL-C and LDL particle measures. Cholesterol efflux, the mechanism by which macrophages in vessel walls secrete cholesterol outside cells, correlates with both surrogate end points and clinical events. The effects of niacin on these alternate measures of HDL have been conflicting. Further studies should determine if modulation of these HDL function markers translates to clinical benefits. Although the HDL cholesterol hypothesis may be defunct, the HDL function hypothesis is now poised to be rigorously tested.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Baigent C et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–78.

    Article  CAS  PubMed  Google Scholar 

  2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344, 1383–1389.

  3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N. Engl. J. Med. 1998; 339, 1349–1357.

  4. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360, 7–22.

  5. Downs JR et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615–22.

    Article  CAS  PubMed  Google Scholar 

  6. Sacks FM et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001–9.

    Article  CAS  PubMed  Google Scholar 

  7. Shepherd J et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301–7.

    Article  CAS  PubMed  Google Scholar 

  8. Cannon CP et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–504.

    Article  CAS  PubMed  Google Scholar 

  9. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62:707–14.

    Article  CAS  PubMed  Google Scholar 

  10. Gordon DJ et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79:8–15.

    Article  CAS  PubMed  Google Scholar 

  11. Bruckert E, Baccara-Dinet M, McCoy F, Chapman J. High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr Med Res Opin. 2005;21:1927–34.

    Article  CAS  PubMed  Google Scholar 

  12. Goff, D. C. et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 01.cir.0000437741.48606.98 (2013). doi:10.1161/01.cir.0000437741.48606.98. Despite the doubts raised about the role of HDL-C in cardiovascular risk reduction, HDL-C is still included in the latest version of the ACC/AHA risk stratification guidelines.

  13. Perk J et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33:1635–701.

    Article  CAS  PubMed  Google Scholar 

  14. Moffatt RJ, Chelland SA, Pecott DL, Stamford BA. Acute exposure to environmental tobacco smoke reduces HDL-C and HDL2-C. Prev Med. 2004;38:637–41.

    Article  CAS  PubMed  Google Scholar 

  15. Huttunen JK et al. Effect of moderate physical exercise on serum lipoproteins. A controlled clinical trial with special reference to serum high-density lipoproteins. Circulation. 1979;60:1220–9.

    Article  CAS  PubMed  Google Scholar 

  16. Kelley GA, Kelley KS. Aerobic exercise and lipids and lipoproteins in men: a meta-analysis of randomized controlled trials. J Mens Health Gend. 2006;3:61–70.

    Article  PubMed Central  PubMed  Google Scholar 

  17. Kodama S et al. Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis. Arch Intern Med. 2007;167:999–1008.

    Article  CAS  PubMed  Google Scholar 

  18. Rimm EB, Williams P, Fosher K, Criqui M, Stampfer MJ. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ. 1999;319:1523–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285, 2486–2497.

  20. Nissen SE et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217–25.

    Article  CAS  PubMed  Google Scholar 

  21. Sacks FM, Expert Group on HDL Cholesterol. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol. 2002;90:139–43.

    Article  CAS  PubMed  Google Scholar 

  22. Belalcazar LM, Ballantyne CM. Defining specific goals of therapy in treating dyslipidemia in the patient with low high-density lipoprotein cholesterol. Prog Cardiovasc Dis. 1998;41:151–74.

    Article  CAS  PubMed  Google Scholar 

  23. Birjmohun RS, Hutten BA, Kastelein JJP, Stroes ESG. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2005;45:185–97.

    Article  CAS  PubMed  Google Scholar 

  24. Manninen V et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988;260:641–51.

    Article  CAS  PubMed  Google Scholar 

  25. Rubins HB et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410–8.

    Article  CAS  PubMed  Google Scholar 

  26. Robins SJ et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA. 2001;285:1585–91.

    Article  CAS  PubMed  Google Scholar 

  27. Kelley GA, Kelley KS, Tran ZV. Walking, lipids, and lipoproteins: a meta-analysis of randomized controlled trials. Prev Med. 2004;38:651–61.

    Article  CAS  PubMed  Google Scholar 

  28. Clofibrate and niacin in coronary heart disease. JAMA. 1975; 231, 360–381.

  29. Canner PL et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245–55.

    Article  CAS  PubMed  Google Scholar 

  30. Brown BG et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583–92.

    Article  CAS  PubMed  Google Scholar 

  31. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512–7.

    Article  CAS  PubMed  Google Scholar 

  32. Villines TC et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol. 2010;55:2721–6.

    Article  PubMed  Google Scholar 

  33. AIM-HIGH Investigators et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–67. AIM-HIGH was the first double-blind, randomized, multicenter trial to assess the effect on cardiovascular events of adding extended-release niacin to statin-treated patients with established ASCVD and atherogenic dyslipidemia with well-controlled LDL-C. The study demonstrated a lack of efficacy of niacin in improving cardiovascular outcomes and was halted early after 3 years of follow-up.

    Article  Google Scholar 

  34. HPS2-THRIVE Collaborative Group et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203–12. HPS2-THRIVE was another double-blind, randomized, multicenter trial that studied the effect on cardiovascular events of adding extended-release niacin/laropiprant versus placebo in statin-treated patients with known vascular disease. This trial was also stopped early after 3.9 years due to lack of reduction in major vascular events in the niacin group. In addition, significantly increased adverse effects were noted with niacin use.

    Article  Google Scholar 

  35. Nicholls SJ. Is niacin ineffective? Or did AIM-HIGH miss its target? Cleve Clin J Med. 2012;79:38–43.

    Article  PubMed  Google Scholar 

  36. Nicholls SJ. Niacin’s effect on cardiovascular risk: have we finally learned our lesson? Cleve Clin J Med. 2014;81:275–7.

    Article  PubMed  Google Scholar 

  37. Song W-L et al. Niacin and biosynthesis of PGD2 by platelet COX-1 in mice and humans. J Clin Invest. 2012;122:1459–68.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  38. Barter PJ et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23:160–7.

    Article  CAS  PubMed  Google Scholar 

  39. Barter PJ et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–22.

    Article  CAS  PubMed  Google Scholar 

  40. Nissen SE et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356:1304–16.

    Article  CAS  PubMed  Google Scholar 

  41. Schwartz GG et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089–99.

    Article  CAS  PubMed  Google Scholar 

  42. Ishigami M et al. Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins. J Biochem. 1994;116:257–62.

    CAS  PubMed  Google Scholar 

  43. Nicholls SJ, Tuzcu EM, Brennan DM, Tardif J-C, Nissen SE. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis clinical perspective: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation. 2008;118:2506–14.

    Article  CAS  PubMed  Google Scholar 

  44. Mani P et al. Relation of high-density lipoprotein cholesterol:apolipoprotein a-I ratio to progression of coronary atherosclerosis in statin-treated patients. Am J Cardiol. 2014;114:681–5.

    Article  CAS  PubMed  Google Scholar 

  45. Yvan-Charvet L et al. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler Thromb Vasc Biol. 2007;27:1132–8.

    Article  CAS  PubMed  Google Scholar 

  46. Cannon CP et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363:2406–15.

    Article  CAS  PubMed  Google Scholar 

  47. Nicholls SJ et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA. 2011;306:2099–109.

    Article  CAS  PubMed  Google Scholar 

  48. Shah PK et al. Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation. 1998;97:780–5.

    Article  CAS  PubMed  Google Scholar 

  49. Nissen SE et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292–300.

    Article  CAS  PubMed  Google Scholar 

  50. Ohashi R, Mu H, Wang X, Yao Q, Chen C. Reverse cholesterol transport and cholesterol efflux in atherosclerosis. QJM. 2005;98:845–56.

    Article  CAS  PubMed  Google Scholar 

  51. Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab. 2008;7:365–75.

    Article  CAS  PubMed  Google Scholar 

  52. Shih DM et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998;394:284–7.

    Article  CAS  PubMed  Google Scholar 

  53. Yuhanna IS et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med. 2001;7:853–7.

    Article  CAS  PubMed  Google Scholar 

  54. Seetharam D et al. High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. Circ Res. 2006;98:63–72.

    Article  CAS  PubMed  Google Scholar 

  55. Kimura T et al. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler Thromb Vasc Biol. 2003;23:1283–8.

    Article  CAS  PubMed  Google Scholar 

  56. Khera AV et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127–35. This study was the first to show a correlation between cholesterol efflux capacity and prevalent CIMT and angiographic coronary disease, even after adjusting for other HDL measures including HDL-C and ApoA-I.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  57. Rohatgi A et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371:2383–93. This study, an analysis of the Dallas Heart Study cohort, showed that baseline cholesterol efflux capacity is inversely associated with incidence of cardiovascular events.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  58. Yvan-Charvet L et al. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol. 2010;30:1430–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  59. Morgan JM, De la Llera-Moya M, Capuzzi DM. Effects of niacin and Niaspan on HDL lipoprotein cellular SR-BI-mediated cholesterol efflux. J Clin Lipidol. 2007;1:614–9.

    Article  PubMed  Google Scholar 

  60. Franceschini G et al. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients. J Clin Lipidol. 2013;7:414–22.

    Article  PubMed  Google Scholar 

  61. Khera AV, Patel PJ, Reilly MP, Rader DJ. The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality. J Am Coll Cardiol. 2013;62:1909–10.

    Article  CAS  PubMed  Google Scholar 

  62. Alrasadi K et al. Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g). Am J Cardiol. 2008;102:1341–7.

    Article  CAS  PubMed  Google Scholar 

  63. Boekholdt SM et al. Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. Circulation. 2013;128:1504–12. This meta-analysis showed that both HDL-C and ApoA-I levels were inversely associated with risk of cardiovascular events. However, while increases in ApoA-I were associated with reduced risk of events, increases in HDL-C were not.

    Article  CAS  PubMed  Google Scholar 

  64. Bays HE et al. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol. 2003;91:667–72.

    Article  CAS  PubMed  Google Scholar 

  65. Capuzzi DM et al. Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. Am J Cardiol. 2003;91:1304–10.

    Article  CAS  PubMed  Google Scholar 

  66. Lamon-Fava S et al. Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. Arterioscler Thromb Vasc Biol. 2008;28:1672–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  67. Airan-Javia SL et al. Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy. Am Heart J. 2009;157:687.e1–8.

    Article  Google Scholar 

  68. Mackey RH et al. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J Am Coll Cardiol. 2012;60:508–16.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  69. Mora S, Glynn RJ, Ridker PM. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation. 2013;128:1189–97.

    Article  CAS  PubMed  Google Scholar 

  70. El Harchaoui K et al. High-density lipoprotein particle size and concentration and coronary risk. Ann Intern Med. 2009;150:84–93.

    Article  PubMed  Google Scholar 

  71. Kuller LH et al. Lipoprotein particles, insulin, adiponectin. C-reactive protein and risk of coronary heart disease among men with metabolic syndrome. Atherosclerosis. 2007;195:122–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  72. Otvos JD et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation. 2006;113:1556–63.

    Article  CAS  PubMed  Google Scholar 

  73. Duprez DA et al. Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Atherosclerosis. 2009;207:524–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  74. Mora S et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2007;192:211–7.

    Article  CAS  PubMed  Google Scholar 

  75. AIM-HIGH Investigators. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH). Am Heart J. 2011;161:471–477.e2.

    Article  Google Scholar 

  76. Bays H, Giezek H, McKenney JM, O’Neill EA, Tershakovec AM. Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus. Metab Syndr Relat Disord. 2012;10:260–6.

    Article  CAS  PubMed  Google Scholar 

  77. Toth PP, Thakker KM, Jiang P, Padley RJ. Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy. Vasc Health Risk Manag. 2012;8:39–44.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  78. Jafri H et al. Extended-release niacin reduces LDL particle number without changing total LDL cholesterol in patients with stable CAD. J Clin Lipidol. 2009;3:45–50.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

P Mani declares no conflicts of interest.

A Rohatgi has received research grants from Merck and a speaker honorarium from Astra Zeneca.

Human and Animal Rights and Informed Consent

All studies by the authors involving animal and/or human subjects were performed after approval by the appropriate institutional review boards. When required, written informed consent was obtained from all participants.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Anand Rohatgi.

Additional information

This article is part of the Topical Collection on Clinical Trials and Their Interpretations

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mani, P., Rohatgi, A. Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?. Curr Atheroscler Rep 17, 43 (2015). https://doi.org/10.1007/s11883-015-0521-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11883-015-0521-x

Keywords

Navigation